Key Takeaways
- 20% revenue growth, 48% PAT jump: Revenue hit ₹2,363 crores and PAT reached ₹231 crores after a one-time Labour Code charge; adjusted PAT grew over 65%, showing the core engine is accelerating.
- Novo Nordisk semaglutide win is a signal, not just a launch: Emcure beat 8-9 competitors to become the exclusive Indian partner for Poviztra, a win management frames as proof it can be the go-to commercialisation partner for global innovators.
- Margins are on a deliberate, multi-year climb: EBITDA margin expanded 110 bps to 19.5% this quarter, and management has laid out a path to add 300-400 bps over 3-5 years, roughly 100 bps per year.
- The balance sheet carries a debt load with a clear unwind plan: Net debt rose to ₹1,203 crores after the Zuventus minority buyout, but management expects it gone in 24-36 months and the company cash-flow positive by end FY28, barring new M&A.
- What to watch next quarter: Whether the Amphotericin B launches across Europe actually begin converting approvals into revenue, the pace of gross margin stabilisation as the Sanofi in-licensing mix matures, and any fine print on the ₹10,000 crore Bio-Pharma SHAKTI scheme.
The Novo Nordisk Partnership & What It Unlocks
- The deal: Emcure secured an exclusive India partnership with Novo Nordisk to launch Poviztra, the innovator semaglutide drug, after a competitive process involving 8-9 other companies.
- Early traction: Launched end-December 2025, the product is available across India and management is happy with initial uptake one month in.
- Strategic signal: Management explicitly positions this win as a proof point that Emcure can be the commercialisation partner of choice for multinationals bringing innovation to India, not just a domestic generic player.
- Pipeline catalyst: The company expects success with Poviztra to attract more such partnerships, framing it as "just harbinger of many more such innovations to follow."
Satish Mehta: "we became the only company to launch the innovator drug in the game-changing semaglutide category."
International Business: The Growth Engine
- Broad-based surge: International revenue grew 24.5% YoY, with Europe up 29.6%, Rest of World up 30.7%, and Canada up 13%.
- Europe's drivers: Growth came from base business ramp-up, Amphotericin B benefits, and the Manx acquisition. Management expects very strong performance to continue into FY27.
- Amphotericin B timing: Approved in 23 European countries but present fully only in the UK so far; most other geographies are either just launching or will launch by end of year, with material revenue contribution expected from next year onwards.
- Amphotericin B moat: Tenders are typically locked in for a couple of years, and Emcure's capacity is probably second only to the innovator; consistent high-volume supply capability should hold them in good stead.
- Rest of World opportunity: The Amphotericin B opportunity outside Europe is equally large and will be launched over time; the liposomal platform is being used to develop at least three more products for filing across markets.
- Canada outlook: Bullish that low-teens growth should continue given a robust pipeline of in-house products.
- Emerging markets biosimilar play: Tenecteplase will be the flagship, with pegaspargase, erythropoietin, and PEGylated filgrastim following in a phase-wise approach across markets.
- Lenacapavir progress: API validation batches completed at a US FDA-approved facility; formulation work at similar status with plans to execute batches. Management calls it a revolutionary HIV introduction but declines to size the market.
Samit Mehta: "Again, I can't put a number to the market potential, though we think it's a revolutionary introduction in the field of HIV, both therapeutically and prophylactically, it offers the opportunity for cure. So market could be huge."
Domestic Business & Therapy Mix
- Chronic-led growth: Domestic business grew 15% YoY, led by cardio-diabeto, CNS, and oncology, while derma and consumer segments continue to scale.
- Chronic/acute split: Chronic is now roughly 50-50 with acute and is expected to do better going forward.
- Cardiac positioning: With the complementary Sanofi in-licensing portfolio, Emcure is now overall the fourth-largest company in the Indian cardiac segment.
- MR productivity: Improved from 6-6.1 last year to about 7 currently, with higher productivity in chronic and Women's Health segments.
- Industry backdrop: Management expects the domestic industry to grow at healthy high single-digits or possibly double-digits, and Emcure aspires to outperform that.
Margin Structure & the Path to 23-24%
- Q3 margin walk: EBITDA margin expanded 110 bps to 19.5% despite investment in new initiatives and the Sanofi in-licensing drag, demonstrating operating leverage.
- Gross margin pressure: Fell to 59.3% from 60.1% due to the Sanofi OAD portfolio in-licensing, business mix (higher international share), and product mix within geographies. For FY26, management expects to stay in the ~60% ballpark.
- The 3-5 year margin ambition: Management anticipates at least 300-400 bps improvement in EBITDA margin over a 3-5 year horizon, with roughly 100 bps improvement year-on-year for the next 2-3 years, targeting 23-24%.
- In-licensing guardrails: Deals are targeted with at least a double-digit EBITDA margin profile and synergies to the rest of the portfolio; most carry little to zero upfront payment and are cash-flow accretive from day one.
- R&D spend: Will inch up in absolute terms but be maintained in the traditional range as a percent of top line.
- Currency note: No significant benefit from favourable currency at the gross margin level because imports also come in dollar terms where the currency hit is incurred.
Vikas Thapar: "over a 3- to 5-year horizon, we would anticipate at least a 300 to 400 basis point improvement in our EBITDA margin profile with roughly 100 basis points or so improvement year-on-year for the next 2 to 3 years is what we have guided to in the past as well."
Balance Sheet & Capital Allocation
- Debt spike: Net debt increased to ₹1,203 crores primarily due to the payout for the Zuventus minority stake.
- Debt reduction timeline: Management expects net debt to go off the balance sheet in the next 24 to 36 months.
- Cash flow target: By end FY28, the company should be cash flow positive, barring any other acquisitions.
- Capex run-rate: Gross block addition of ₹350-400 crores per year for the next 2-3 years.
- Labour Code charge: An exceptional expense of ₹38 crores was taken during the quarter related to Labour Code changes.
Policy Tailwind: Bio-Pharma SHAKTI
- The scheme: The February 2026 Union Budget earmarked ₹10,000 crores for Bio-Pharma SHAKTI to encourage biosimilars and biologics, specifically mentioning oncology, diabetes, and rare disease.
- Emcure's positioning: Gennova is active in all these disease areas, especially oncology, positioning the group to benefit once the fine print emerges.
- Ecosystem enablers: The scheme also targets setting up 1,000 clinical trial centres (speeding patient recruitment), strengthening NIPERs with biologics capabilities, and bringing CDSCO regulatory processes in line with global best practices.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Low to mid-teens compounded growth rate | 3-5 year horizon |
| FY27 revenue guidance | Similar to ~13% growth guided for FY26, which the company is tracking slightly ahead of | FY27 |
| EBITDA margin improvement | At least 300-400 bps total improvement, roughly 100 bps per year, targeting 23-24% | 3-5 years |
| International market growth (Europe & Canada) | Compounded low-teens growth rate | 3-5 years |
| Net debt reduction | Net debt to go off the balance sheet | 24-36 months |
| Cash flow positive | Company should be cash flow positive, barring acquisitions | By end FY28 |
| Annual capex | ₹350-400 crores gross block addition per year | Next 2-3 years |
| Amphotericin B Europe launches | Launches across Europe | By end of year |
| Amphotericin B revenue contribution | Material growth expected | From next year onwards |
| Canada growth | Mid-teens growth | Current year |
| Gross margin | In the ~60% ballpark | FY26 |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue from operations | ₹2,363 cr, +20.4% YoY |
| Domestic revenue | ₹1,025 cr, +15.4% YoY |
| International revenue | ₹1,338 cr, +24.5% YoY |
| Europe revenue | ₹464 cr, +29.6% YoY |
| Canada revenue | ₹397 cr, +12.8% YoY |
| Emerging markets revenue | ₹477 cr, +30.7% YoY |
| Gross margin | 59.3%, vs 60.1% in Q3 FY25; decline due to Sanofi OAD in-licensing and business mix |
| EBITDA | ₹460 cr, +27.2% YoY, excluding other income |
| EBITDA margin | 19.5%, vs 18.4% in Q3 FY25 and 19.3% in Q2 FY26 |
| Profit after tax | ₹231 cr, +48% YoY; includes exceptional expense of ₹38 cr for Labour Code |
| Adjusted PAT | ₹260 cr, +65% YoY, excluding Labour Code impact |
| Net debt | ₹1,203 cr; increase primarily due to Zuventus minority stake payout |
| Domestic base business growth | 10%+, ex of Sanofi OAD in-licensing portfolio |
| In-licensing contribution to total revenue | 6% to 7% of total revenue; low to mid-teens of domestic business |
| MR productivity | ~7, vs 6 to 6.1 in same quarter last year |